Fiera Capital Corp Decreases Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Fiera Capital Corp trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,219,189 shares of the company's stock after selling 38,775 shares during the period. Fiera Capital Corp owned approximately 1.64% of SpringWorks Therapeutics worth $44,049,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Creative Planning bought a new position in SpringWorks Therapeutics during the 3rd quarter valued at $254,000. Mirae Asset Global Investments Co. Ltd. increased its stake in SpringWorks Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company's stock valued at $87,000 after buying an additional 474 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in SpringWorks Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,285 shares of the company's stock valued at $458,000 after buying an additional 5,582 shares during the period. Principal Financial Group Inc. increased its stake in SpringWorks Therapeutics by 102.5% during the 3rd quarter. Principal Financial Group Inc. now owns 918,445 shares of the company's stock valued at $29,427,000 after buying an additional 464,903 shares during the period. Finally, Assetmark Inc. grew its stake in shares of SpringWorks Therapeutics by 13.7% in the 3rd quarter. Assetmark Inc. now owns 46,020 shares of the company's stock worth $1,474,000 after purchasing an additional 5,546 shares during the last quarter.

SpringWorks Therapeutics Trading Down 2.0 %

Shares of NASDAQ:SWTX traded down $1.16 during mid-day trading on Friday, reaching $57.43. The stock had a trading volume of 2,778,360 shares, compared to its average volume of 1,684,477. The firm has a market cap of $4.27 billion, a PE ratio of -14.80 and a beta of 0.81. The firm has a 50 day simple moving average of $39.35 and a two-hundred day simple moving average of $36.86. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $60.00.

Insiders Place Their Bets

In other news, CEO Saqib Islam sold 48,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $53.30, for a total value of $2,558,400.00. Following the sale, the chief executive officer now directly owns 1,002,502 shares in the company, valued at $53,433,356.60. This trade represents a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Badreddin Edris sold 20,000 shares of the firm's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total transaction of $839,400.00. Following the completion of the transaction, the chief operating officer now directly owns 209,600 shares of the company's stock, valued at $8,796,912. This represents a 8.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 302,750 shares of company stock worth $16,139,410. Company insiders own 7.61% of the company's stock.

Wall Street Analysts Forecast Growth

SWTX has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Wednesday. Evercore ISI raised their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday. Wedbush reiterated an "outperform" rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a research note on Monday, February 10th. Finally, Guggenheim dropped their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $70.83.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.